- Biomerica (NASDAQ:BMRA) has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of its new Helicobacter pylori test, called hp+detect.
- The hp+detect product has been developed for the identification and monitoring of H. pylori infection, the leading cause of duodenal and gastric ulcers.
- In order to sell the product in Canada, Biomerica’s distribution partner will now seek Health Canada clearance using clinical data generated by the drug developer.
- The company also intends to seek a CE Mark for the product to be sold in the European Union and FDA clearance in the USA.
- Shares up more than 4% premarket.